Registry of patients with plasma cell disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240608004

Enrollment

5000

Registered

2024-06-08

Start date

2024-06-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plasma cell disorders patient registry plasma cell disorders

Interventions

Patients with plasma cell disorders at Siriraj Hospital, both those diagnosed since 2007 and newly diagnosed.

Other

patients with plasma cell disorders

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged 18 years and above 2.Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014

Exclusion criteria

Exclusion criteria: 1.insufficient data needed for analysis

Design outcomes

Primary

Measure	Time frame
register the plasma cell disorder patients 15 years number of plasma cell disorder patients	—

Secondary

Measure	Time frame
incidence of plasma cell disorders 15 years number of plasma cell disorders both before and after malignancy,Time to progression from premalignant diagnosis to malignant Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM), Progression free survival from diagnosis to progress time to progression free survival,overall survival from diagnosis to death time of survival,influencing factors during treatment factors influencing overall survival, progression-free survival, and time to progression,Symptoms and signs during treatment Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients,genetic characteristics after diagnosis genetic characteristics of plasma cell disorder,cost-effectiveness during treatment cost-effectiveness of plasma cell disorders treatment in Thailand	—

Measure

Time frame

incidence of plasma cell disorders 15 years number of plasma cell disorders both before and after malignancy,Time to progression from premalignant diagnosis to malignant Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM), Progression free survival from diagnosis to progress time to progression free survival,overall survival from diagnosis to death time of survival,influencing factors during treatment factors influencing overall survival, progression-free survival, and time to progression,Symptoms and signs during treatment Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients,genetic characteristics after diagnosis genetic characteristics of plasma cell disorder,cost-effectiveness during treatment cost-effectiveness of plasma cell disorders treatment in Thailand

—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Faculty of Medicine Siriraj Hospital

chutima.kua@mahidol.ac.th0896790959

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026